CONCLUSION
mutated tumors
HS‐10352, administered at 6 mg once‐daily, was well‐tolerated in patients with HR‐positive, HER2‐negative ABC and showed promising antitumor activity, particularly in individuals with PIK3CA mutated tumors. These findings lend support to the further clinical development of HS‐10352, including its potential use in combination therapies such as endocrine therapy.